ReviewNeuroImage2026
Advanced diffusion MRI tract signatures in Alzheimer's disease, dementia with Lewy bodies, and the FTD/PPA spectrum.
Review in NeuroImage, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Alzheimer's disease (AD), Dementia with Lewy bodies (DLB), frontotemporal dementia (FTD), and primary progressive aphasia (PPA) are heterogeneous neurodegenerative syndromes with overlapping clinical features and substantial societal burden. Their phenotypic diversity, including atypical AD variants and multiple PPA subtypes, poses major challenges for early diagnosis and disease monitoring. Sensitive, non-invasive imaging biomarkers remain limited. Diffusion magnetic resonance imaging (dMRI) has evolved beyond conventional diffusion tensor imaging (DTI) to include multi-shell models such as neurite orientation dispersion and density imaging (NODDI), free-water imaging (FWI), and fixel-based analysis (FBA), which offer increased microstructural specificity by probing neurite organization, extracellular water content, and fiber-specific degeneration. In this review of 54 dMRI studies spanning AD, DLB, FTD, and PPA spectrums, we identify both convergent microstructural patterns shared across techniques and disease-specific signatures revealed by advanced models. Canonical DTI findings demonstrate consistent syndrome-related alterations, including fornix and cingulum involvement in AD, widespread diffusivity increases in DLB, uncinate fasciculus degeneration in FTD, and arcuate fasciculus disruption in PPA. Advanced dMRI methods extend these observations by revealing disease-specific neurite and free-water alterations, associations with molecular imaging markers, and improved sensitivity to clinical severity, longitudinal cognitive decline, and microstructural progression. Across syndromes and subtypes, NODDI- and FBA-based metrics consistently outperform conventional DTI. Together, this review provides a comprehensive framework for interpreting advanced dMRI markers across the AD, DLB, and the FTD-PPA spectrum, and highlights their potential for refining disease characterization and tracking neurodegenerative progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.